Future perspectives for the development of P-glycoprotein modulators

Drug Resistance Updates

Volumn 1, Issue 3, 1998, Pages 190-200

  Sandor, Victor ^a   Fojo, Tito ^a   Bates, Susan E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001223675     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-7646(98)80039-3     Document Type: Review

References (130)

1. 10-methyl-pteroylglutamic acid in a strain of transmitted mouse leukemia. Science 111 (1950) 116-117
2. Lehnert M. Clinical multidrug resistance in cancer: a multifactorial problem. Eur J Cancer 32A (1996) 912-920
3. Juliano R., and Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455 (1976) 152-162
4. Roninson I.B., Chin J.E., Choi K.G., et al. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA 83 (1986) 4538-4542
5. Fojo A.T., Ueda K., Slamon D.J., et al. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84 (1987) 265-269
6. Gottesman M.M., and Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem 62 (1993) 385-427
7. Goldstein L.J., Galski H., Fojo A., et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81 (1989) 116-124
8. Tew K.D. Modulation of p-glycoprotein-mediated drug resistance. In: Tew K.D., Houghton P.J., and Houghton J.A. (Eds). Preclinical and Clinical Modulation of Anticancer Drugs (1993), CRC Press 125-196
9. Ling V. P-glycoprotein and resistance to anticancer drugs. Cancer 69 (1992) 2603-2609
10. Ferry D.R., Traunecker H., and Kerr D.J. Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer 32A (1996) 1070-1081
11. Ford J.M., and Hait W.N. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42 (1990) 155-199
12. Tsuruo T., Iida H., Tsukagoshi S., et al. Increased accumulation of vincristine and adriamycin in drug resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 42 (1982) 4730-4733
13. Slater L.M., Sweet P., Stupecky M., et al. Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma. Br J Cancer 54 (1986) 235-238
14. Boesch D., Muller K., Pourtier-Manzanedo A., et al. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmuno-suppressive cyclosporin derivative. Exp Cell Res 196 (1991) 26-32
15. Ford J.M., Prozialeck W.C., and Hait W.N. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol Pharmacol 35 (1989) 105-115
16. Fleming G.F., Amato J.M., Agresti M., et al. Megesterol acetate reverses multidrug resistance and interacts with P-glycoprotein. Cancer Chemother Pharmacol 29 (1992) 445-449
17. Ramu A., Glaubiger D., and Fuks Z. Reversal of acquired drug resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues. Cancer Res 44 (1984) 4392-4395
18. Chauffert B., Martini M., Hammann A., et al. Amiodarone-induced enhancement of doxorubicin and 4′-deoxydoxorubicin cytotoxicity to rat colon cancer cells in vitro and in vivo. Cancer Res 46 (1986) 825-830
19. Tsuruo T., Iida H., Kitatani Y., et al. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug resistant tumor cells. Cancer Res 44 (1984) 4303-4307
20. Beketic-Oreskovic L., Duran G.E., Chen G., et al. Decreased mutation rate for doxorubicin resistance and suppression of mdr-I gene activation by PSC 833. J Natl Cancer Inst 87 (1995) 1593-1596
21. Futscher B., Foley N.E., and Gleason-Guzman M.C. Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance. Int J Cancer 66 (1996) 520-525
22. Morgan S.A., Watson J.V., Twentyman P.R., et al. Flow cytometric analysis of Hoechst 33342 uptake as an indicator of multi-drug resistance in human lung cancer. Br J Cancer 60 (1989) 282-287
23. Coley H.M., Amos W.B., Twentyman P.R., et al. Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines. Br J Cancer 67 (1993) 1316-1323
24. Dordal M.S., Ho A.C., Jackson-Stone M., et al. Flow cytometric assessment of cellular pharmacokinetics of fluorescent drugs. Cytometry 20 (1995) 307-314
25. [published erratum appears in Br J Cancer 1996; 74(12):2042]. Feller N., Kuiper C.M., Lankelma J., et al. Functional detection of MDRI/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry. Br J Cancer 72 (1995) 543-549
26. Krishan A., Sauerteig A., Andritsch I., et al. Flow cytometric analysis of the multiple drug resistance phenotype. Leukemia 11 (1997) 1138-1146
27. Broxterman H.J., Schuurhuis G.J., Lankelma J., et al. Highly sensitive and specific detection of P-glycoprotein function for haematological and solid tumour cells using a novel nucleic acid stain. Br J Cancer 76 (1997) 1029-1034
28. Beck W.T., Cirtain M.C., Look A.T., et al. Reversal of vinca alkaloid resistance but not multiple drug resistance in human leukemic lymphoblasts. Cancer Res 46 (1986) 778-784
29. Fojo A., Akiyama S., Gottesman M.M., et al. Reduced drug accumulation in multiple drug-resistant human KB carcinoma cell lines. Cancer Res 45 (1985) 3002-3007
30. Klohs W.D., Steinkampf R.W., Havlick J.A., et al. Resistance to anthrapyrazols and anthracyclines in multidrug-resistant P388 murine leukemic cells: reversal by calcium channel blockers and calmodulin antagonists. Cancer Res 46 (1986) 4352-4356
31. Greenberger L.M., Williams S.S., and Horwitz S.B. Biosynthesis of heterogenous forms of multidrug resistance associated glycoproteins. J Biol Chem 262 (1987) 13685-13689
32. Richert N., Aldwin L., Nitecki D., et al. Stability and covalent modification of P-glycoprotein in multidrug-resistant KB cells. Biochemistry 27 (1988) 7607-7613
33. Carlsen S.A., Till J.E., and Ling V. Modulation of drug permeability in Chinese-hamster ovary cells. Possible role of phosphorylation of surface glycoproteins. Biochim Biophys Acta 467 (1987) 238-250
34. Ramu A., Ramu N., and Rosario L.M. Circumvention of multidrug-resistance in P388 cells is associated with a rise in cellular content of phosphatidylcholine. Biochem Pharmacol 41 (1991) 1455-1461
35. Goldstein L.J. Clinical reversal of drug resistance. Curr Probl Cancer 19 (1995) 65-124
36. Sandor V., Wilson W., Fojo T., et al. The role of MDR-I in refractory lymphoma. Leuk Lymphoma 28 (1997) 23-31
37. Marie J.P. P-glycoprotein in adult hematological malignancies. Hematol Oncol Clin Am 9 (1995) 239-249
38. Goldstein L.J., Gottesman M.M., and Pastan I. Expression of the MDRI gene in human cancers. Cancer Treat Res 57 (1991) 101-119
39. Herzog C.E., and Bates S.E. Molecular diagnosis of multidrug resistance. In: Goldstein L.J., and Ozols R.F. (Eds). Anticancer Drug Resistance:Advances in Molecular and Clinical Research (1994), Kluwer Academic Publishers, Boca Raton 129-147
40. Rothenberg M.L., Mickley L.A., Cole D.E., et al. Expression of the mdr-1/P-170 gene in patients with acute lymphoblastic leukemia. Blood 74 (1989) 1388-1395
41. Nakagawa M., Emoto A., Nasu N., et al. Clinical significance of multidrug resistance associated protein and P-glycoprotein in patients with bladder cancer. J Urol 157 (1997) 1260-1264
42. Nakagawa Y., Perentes E., and Rubinstein L.J. Immunohistochemical characterization of oligodendrogliomas: an analysis of multiple markers. Acta Neuropathol (Berl) 72 (1986) 15-22
43. Favrot M., Combaret V., Goillot E., et al. Expression of P-glycoprotein restricted to normal cells in neuroblastoma biopsies. Br J Cancer 64 (1991) 233-238
44. Chan H.S., Grogan T.M., Haddad G., et al. P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. J Natl Cancer Inst 89 (1997) 1706-1715
45. Baldini N., Scotlandi K., Barbanti-Brodano G., et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 333 (1995) 1380-1385
46. Chan H.S., Haddad G., Thorner P.S., et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325 (1991) 1608-1614
47. Chan H.S., Thorner P.S., Haddad G., et al. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8 (1990) 689-704
48. Chan H.S., Bradley G., Thorner P., et al. A sensitive method for immunocytochemical detection of P-glycoprotein in multidrug-resistant human ovarian carcinoma cell lines. Lab Invest 59 (1988) 870-875
49. Wallner J., Depisch D., Hopfner M., et al. MDRI gene expression and prognostic factors in primary breast carcinomas. Eur J Cancer 27 (1991) 1352-1355
50. Merkel D.E., Fuqua S.A., Tandon A.K., et al. Electrophoretic analysis of 248 clinical breast cancer specimens for P-glycoprotein overexpression or gene amplification. J Clin Oncol 7 (1989) 1129-1136
51. Verrelle P., Meissonnier F., Fonck Y., et al. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 83 (1991) 111-116
52. Marie J.P., Huet S., Faussat A.M., et al. Multicentric evaluation of the MDR phenotype in leukemia. French Network of the Drug Resistance Intergroup, and Drug Resistance Network of Assistance Publique-Hopitaux de Paris. Leukemia 11 (1997) 1086-1094
53. Solary E., Bidan J.M., Calvo F., et al. P-glycoprotein expression and in vitro reversion of doxorubicin resistance by verapamil in clinical specimens from acute leukaemia and myeloma. Leukemia 5 (1991) 592-597
54. Dalton W.S., Grogan T.M., Meltzer P.S., et al. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7 (1989) 415-424
55. Fojo A.T., Shen D.W., Mickley L.A., et al. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J Clin Oncol 5 (1987) 1922-1927
56. Campos L., Guyotat D., Archimbaud E., et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 79 (1992) 473-476
57. Goasguen J.E., Dossot J.M., Fardel O., et al. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 81 (1993) 2394-2398
58. [published erratum appears in Blood 1995; 86(12):4710]. Kang Y.K., Zhan Z., Regis J., et al. Expression of mdr-1 in refractory lymphoma: quantitation by polymerase chain reaction and validation of the assay. Blood 86 (1995) 1515-1524
59. Pileri S.A., Sabattini E., Falini B., et al. Immunohistochemical detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas. Histopathology 19 (1991) 131-140
60. Arao S., Suwa H., Mandai M., et al. Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer. Cancer Res 54 (1994) 1355-1359
61. Holzmayer T.A., Hilsenbeck S., Von H.D., et al. Clinical correlates of MDRI (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst 84 (1992) 1486-1491
62. Beck W.T., Grogan T.M., Willman C.L., et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 56 (1996) 3010-3020
63. Herzog C.E., Trepel J.B., Mickley L.A., et al. Various methods of analysis of mdr-1/P-glycoprotein in human colon cancer cell lines. J Natl Cancer Inst 84 (1992) 711-716
64. Nakagawara A., Kadomastu K., Sato S.I., et al. Inverse correlation between expression of multidrug resistance gene and c-myc oncogene in human neuroblastomas. Cancer Res 50 (1990) 3043-3047
65. Rao V.V., Anthony D.C., and Piwnica-Worms D. Multidrug resistance P-glycoprotein monoclonal antibody JSB-1 crossreacts with pyruvate carboxylase. J Histochem Cytochem 43 (1995) 1187-1192
66. mdr-1. J Natl Cancer Inst 89 (1997) 1524-1529
67. [published erratum appears in Br J Cancer 1991;63(1): 164-165]. Schlaifer D., Laurent G., Chittal S., et al. Immunohistochemical detection of multidrug resistance associated P-glycoprotein in tumour and stromal cells of human cancers. Br J Cancer 62 (1990) 177-182
68. - cases. Blood 86 (1995) 2329-2342
69. Relling M.V. Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs?. Ther Drug Monit 18 (1996) 350-356
70. Lyubimov E., Lan L.B., Pashinsky I., et al. Effect of modulators of the multidrug resistance pump on the distribution of vinblastine in tissues of the mouse. Anticancer Drugs 7 (1996) 60-69
71. Didier A.D., and Loor F. Decreased biotolerability for ivermectin and cyclosporin A in mice exposed to potent P-glycoprotein inhibitors. Int J Cancer 63 (1995) 263-267
72. Mayer U., Wagenaar E., Dorobek B., et al. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest 100 (1997) 2430-2436
73. Echizen H., Brecht T., and Niedergresass S. The effect of dextro-, levo- and racemic verapamil on atrioventricular conduction in humans. Am Heart J 109 (1985) 210-215
74. Plumb J.A., Milroy R., and Kaye S.B. The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific. Biochem Pharmacol 39 (1990) 787-792
75. Tolcher A.W., Cowan K.H., Solomon D., et al. Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. J Clin Oncol 14 (1996) 1173-1184
76. Jones R.D., Kerr D.J., Harnett A., et al. A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer. Br J Cancer 62 (1990) 133-135
77. Wishart G.C., Plumb J.A., Morrison J.G., et al. Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo. Eur J Cancer 28 (1992) 28-31
78. Twentyman P.R., Fox N.E., and White D.J.G. Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell line. Br J Cancer 56 (1987) 55-57
79. Twentyman P.R. Modifiers of multidrug resistance. Br J Haematol 90 (1995) 735-737
80. Keller R.P., Altermatt H.J., Nooter K., et al. SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia. Int J Cancer 50 (1992) 593-597
81. Boesch D., Muller K., Pourtier-Manzanedo A., et al. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. Exp Cell Res 196 (1991) 26-32
82. Lush R.M., Meadows B., Fojo A.T., et al. Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist. J Clin Pharmacol 37 (1997) 123-128
83. Boote D.J., Dennis I.F., Twentyman P.R., et al. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 14 (1996) 610-618
84. Yamazaki M., Suzuki H., and Sugiyama Y. Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm Res 13 (1996) 497-513
85. Bissett D., Kerr D.J., Cassidy J., et al. Phase I and pharmacokinetic study of D-verapamil and doxorubicin. Br J Cancer 64 (1991) 1168-1171
86. Kerr D.J., Graham J., Cummings J., et al. The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol 18 (1986) 239-242
87. Wilson W.H., Jamis-Dow C., Bryant G., et al. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. J Clin Oncol 13 (1995) 1985-1994
88. Lum B.L., Kaubisch S., Yahanda A.M., et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10 (1992) 1635-1642
89. Rushing D.A., Raber S.R., Rodvold K.A., et al. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. Cancer 74 (1994) 834-841
90. Watanabe T., Iwasaki M., Todaka T., et al. Effect of SDZ PSC 833 ([3′-keto-Bmtl]-[Val2]-cyclosporin) on serum protein binding and distribution to blood cells of doxorubicin, vincristine and etoposide in vitro. Anticancer Drugs 8 (1997) 400-404
91. Sonneveld P., Marie J.P., Huisman C., et al. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. Leukemia 10 (1996) 1741-1750
92. List A.F., Spier C., Greer J., et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 11 (1993) 1652-1660
93. Ludescher C., Eisterer W., Hilbe W., et al. Decreased potency of MDR-modulators under serum conditions determined by a functional assay. Br J Haematol 91 (1995) 652-657
94. Lehnert M., de Giuli R., Kunke K., et al. Serum can inhibit reversal of multidrug resistance by chemosensitizers. Eur J Cancer 32A (1996) 862-867
95. Lehnert M., de Giuli R., and Twentyman P.R. Sensitive and rapid bioassay for analysis of p-glycoprotein-inhibiting activity of chemosensitizers in patient serum. Clin Cancer Res 2 (1996) 403-410
96. Ayesh S., Lyubimov E., Algour N., et al. Reversal of P-glycoprotein is greatly reduced by the presence of plasma but can be monitored by an ex vivo clinical assay. Anticancer Drugs 7 (1996) 678-686
97. Dalton W.S., Crowley J.J., Salmon S.S., et al. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Cancer 75 (1995) 815-820
98. Millward M.J., Cantwell B.M., Munro N.C., et al. Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study. Br J Cancer 67 (1993) 1031-1035
99. Milroy R. A randomized clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group. Br J Cancer 68 (1993) 813-818
100. Gatzemeier U., Kampf S., and von Pawel J. Randomized trial of vindesine and etoposide +/- dexverapamil in advanced non-small cell lung cancer:first results. J Cancer Res Clin Oncol 121 Suppl 3 (1995) R17-R21
101. Wishart G.C., Bissett D., Paul J., et al. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J Clin Oncol 12 (1994) 1771-1777
102. Trock B.J., Leonessa F., and Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDRI/gp170 expression and its possible functional significance. J Natl Cancer Inst 89 (1997) 917-931
103. Solary E., Witz B., Caillot D., et al. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood 88 (1996) 1198-1205
104. Hosking L.K., Whelan R.D., Shellard S.A., et al. Multiple mechanisms of resistance in a series of human testicular teratoma cell lines selected for increasing resistance to etoposide. Int J Cancer 57 (1994) 259-267
105. McGrath T., Marquardt D., and Center M.S. Multiple mechanisms of adriamycin resistance in the human leukemia cell line CCRF-CEM. Biochem Pharmacol 38 (1989) 497-501
106. Hyafil F., Vergely C., Du V.P., et al. In vitro and in vivo reversal of multidrug resistance by GF 120918, an acridonecarboxamide derivative. Cancer Res 53 (1993) 4595-4602
107. Zhou D.C., Simonin G., Faussat A.M., et al. Effect of the multidrug inhibitor GG918 on drug sensitivity of human leukemic cells. Leukemia 11 (1997) 1516-1522
108. Dantzig A.H., Shepard R.L., Cao J., et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 56 (1996) 4171-4179
109. Starling J.J., Shepard R.L., Cao J., et al. Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein. Adv Enzyme Regul 37 (1997) 335-347
110. Germann U.A., Shlyakhter D., Mason V.S., et al. Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs 8 (1997) 125-140
111. Germann U.A., Ford P.J., Shlyakhter D., et al. Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Anticancer Drugs 8 (1997) 141-155
112. DiDiodato G., and Sharom F.J. Interaction of combinations of drugs, chemosensitizers, and peptides with the P-glycoprotein multidrug transporter. Biochem Pharmacol 53 (1997) 1789-1797
113. Shao Y.M., Ayesh S., and Stein W.D. Mutually co-operative interactions between modulators of P-glycoprotein. Biochim Biophys Acta 1360 (1997) 30-38
114. Lyubimov E., Lan L.B., Pashinsky I., et al. Saturation reversal of the multidrug pump using many reversers in low-dose combinations. Anticancer Drugs 6 (1995) 727-735
115. Stein W.D. Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. Physiol Rev 77 (1997) 545-590
116. Ballinger J.R., Muzzammil T., and Moore M.J. Technetium-99 m-furifosmin as an agent for functional imaging of multidrug resistance in tumors. J Nucl Med 38 (1997) 1915-1919
117. Cordobes M.D., Starzec A., Delmon-Moingeon L., et al. Technetium-99 m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression. J Nucl Med 37 (1996) 286-289
118. Del Vecchio S., Ciarmiello A., Pace L., et al. Fractional retention of technetium-99 m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. J Nucl Med 38 (1997) 1348-1351
119. Del Vecchio S.D., Ciarmiello A., Potena M.I., et al. In vivo detection of multidrug-resistant (MDRI) phenotype by technetium-99 m sestamibi scan in untreated breast cancer patients. Eur J Nucl Med 24 (1997) 150-159
120. Piwnica-Worms D., Chiu M.L., Budding M., et al. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 53 (1993) 1-8
121. Luker G.D., Fracasso P.M., Dobkin J., et al. Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99 m-sestamibi in vivo. J Nucl Med 38 (1997) 369-372
122. Chen C., Meadows B., Regis J., et al. Detection of in vitro P-glycoprotein inhibition by PSC 833 using Tc-99m Sestamibi. Clin Cancer Res 8 (1997) 545-552
123. Krishna R., and Mayer L.D. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug resistant solid tumours. Cancer Res 57 (1997) 5246-5253
124. Kool M., deHaas M., Scheffer G.L., et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRPI), in human cancer cell lines. Cancer Treat Res 57 (1997) 3537-3547
125. Cole S.P.C., Bhardwaj G., Gerlach J.H., et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258 (1992) 1650-1654
126. Slovak M.L., Ho J.P., Cole S.P., et al. The LRP gene encoding a major vault protein associated with drug resistance maps proximal to MRP on chromosome 16: evidence that chromosome breakage plays a key role in MRP or LRP gene amplification. Cancer Res 55 (1995) 4214-4219
127. Izquierdo M.A., van der Zee A.G., Vermorken J.B., et al. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 87 (1995) 1230-1237
128. Lee J.S., Scala S., Matsumoto Y., et al. Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression. J Cell Biochem 65 (1997) 513-526
129. Barrand M.A., Rhodes T., Center M.S., et al. Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190 k membrane protein distinct from P-glycoprotein. Eur J Cancer 29A (1993) 408-415
130. Lee J.S., Paull K., Alvarez M., et al. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol 47 (1994) 627-638